Oragenics, Inc. (OGEN) Updates on its potential COVID-19 Vaccine, expects to file an IND in 2021
The biotechnology firm is developing its vaccine candidate against SARS-CoV-2. Oragenics anticipate the Phase 1 trial of TerraCoV2 beginning in mid-2021 following the approval in 2023. Shares of Oragenics, Inc. (OGEN) made a strong movement on Wednesday following the Zacks Small-Cap Research that revealed OGEN’s plans and development of its novel COVID-19 vaccine candidate, TerraCoV2. […]
